Abstract
Dehydroepiandrosterone (DHEA) is a metabolic intermediate in the biosynthesis of estrogens and androgens with a past clouded in controversy and bold claims. It was once touted as a wonder drug, a fountain of youth that could cure all ailments. However, in the 1980s DHEA was banned by the FDA given a lack of documented health benefits and long-term use data. DHEA had a revival in 1994 when it was released for open market sale as a nutritional supplement under the Dietary Supplement Health and Safety Act. Since that time, there has been encouraging research on the hormone, including randomized controlled trials and subsequent meta-analyses on various conditions that DHEA may benefit. Bone health has been of particular interest, as many of the metabolites of DHEA are known to be involved in bone homeostasis, specifically estrogen and testosterone. Studies demonstrate a significant association between DHEA and increased bone mineral density, likely due to DHEA’s ability to increase osteoblast activity and insulin like growth factor 1 (IGF-1) expression. Interestingly, IGF-1 is also known to improve fracture healing, though DHEA, a potent stimulator of IGF-1, has never been tested in this scenario. The aim of this review is to discuss the history and mechanisms of DHEA as they relate to the skeletal system, and to evaluate if DHEA has any role in treating fractures.
Similar content being viewed by others
Data availability
Not applicable
References
Baulieu EE (1996) Dehydroepiandrosterone (DHEA): a fountain of youth? J Clin Endocrinol Metab 81:3147–3151
Gaby A (1996) Dehydroepiandrosterone: biological effects and clinical significance. Altern Med Rev 1:60–69
Nestler J (1995) DHEA: a coming of age. Ann N Y Acad Sci 774:ix–xi
Gurnell EM, Hunt PJ, Curran SE, Conway CL, Pullenayegum EM, Huppert FA, Compston JE, Herbert J, Chatterjee VK (2008) Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial. J Clin Endocrinol Metab 93:400–409
Jankowski CM, Gozansky WS, Schwartz RS, Dahl DJ, Kittelson JM, Scott SM, Van Pelt RE, Kohrt WM (2006) Effects of dehydroepiandrosterone replacement therapy on bone mineral density in older adults: a randomized, controlled trial. J Clin Endocrinol Metab 91:2986–2993
Villareal DT, Holloszy JO, Kohrt WM (2000) Effects of DHEA replacement on bone mineral density and body composition in elderly women and men. Clin Endocrinol 53:561–568
von Muhlen D, Laughlin GA, Kritz-Silverstein D, Bergstrom J, Bettencourt R (2008) Effect of dehydroepiandrosterone supplementation on bone mineral density, bone markers, and body composition in older adults: the DAWN trial. Osteoporos Int 19:699–707
Kaivosoja E, Sariola V, Chen Y, Konttinen YT (2015) The effect of pulsed electromagnetic fields and dehydroepiandrosterone on viability and osteo-induction of human mesenchymal stem cells. J Tissue Eng Regen Med 9:31–40
Butenandt A, Dannenbaum H (1934) Isolierung eines neuen, physiologisch unwirksamen Sterinderivates aus Mannerharn, seine Verknupfung mit Dehydro-androsteron und Androsteron. Z Physiol Chem 229:192–195
Munson P, Gallagher T, Koch F (1944) Isolation of dehydroisoandrosterone sulfate from normal male urine. J Biol Chem 152:67–77
Lieberman S (1995) An abbreviated account of some aspects of the biochemistry of DHEA, 1934-1995. Ann N Y Acad Sci 774:1–15
Fieser L, Fieser M (1959) Steroids. New York, Reinhold Publishing Corporation
Migeon CJ, Plager JE (1954) Identification and isolation of dehydroisoandrosterone from peripheral human plasma. J Biol Chem 209:767–772
Deneve L, Vermeulen A (1965) The determination of 17-oxosteroid sulphates in human plasma. J Endocrinol 32:295–302
Cupp, Melanie Johns, and Timothy S Tracy. 2002. Dietary supplements: toxicology and clinical pharmacology (Springer Science & Business Media).
Rutkowski K, Sowa P, Rutkowska-Talipska J, Kuryliszyn-Moskal A, Rutkowski R (2014) Dehydroepiandrosterone (DHEA): hypes and hopes. Drugs 74:1195–1207
The Dietary Supplement Health and Education Act of 1994." (n.d.)In. 1994. United States of America.
Barrett-Connor E, Khaw KT, Yen SS (1986) A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med 315:1519–1524
Bulbrook RD, Hayward JL, Spicer CC (1971) Relation between urinary androgen and corticoid excretion and subsequent breast cancer. Lancet 2:395–398
Stahl F, Schnorr D, Pilz C, Dorner G (1992) Dehydroepiandrosterone (DHEA) levels in patients with prostatic cancer, heart diseases and under surgery stress. Exp Clin Endocrinol 99:68–70
Coleman DL, Leiter EH, Schwizer RW (1982) Therapeutic effects of dehydroepiandrosterone (DHEA) in diabetic mice. Diabetes 31:830–833
Gordon GB, Bush DE, Weisman HF (1988) Reduction of atherosclerosis by administration of dehydroepiandrosterone. A study in the hypercholesterolemic New Zealand white rabbit with aortic intimal injury. J Clin Invest 82:712–720
Araneo BA, Ryu SY, Barton S, Daynes RA (1995) Dehydroepiandrosterone reduces progressive dermal ischemia caused by thermal injury. J Surg Res 59:250–262
Mills SJ, Ashworth JJ, Gilliver SC, Hardman MJ, Ashcroft GS (2005) The sex steroid precursor DHEA accelerates cutaneous wound healing via the estrogen receptors. J Invest Dermatol 125:1053–1062
Yen SS, Morales AJ, Khorram O (1995) Replacement of DHEA in aging men and women. Potential remedial effects. Ann N Y Acad Sci 774:128–142
Dhatariya K, Bigelow ML, Nair KS (2005) Effect of dehydroepiandrosterone replacement on insulin sensitivity and lipids in hypoadrenal women. Diabetes 54:765–769
Weiss EP, Villareal DT, Fontana L, Han DH, Holloszy JO (2011) Dehydroepiandrosterone (DHEA) replacement decreases insulin resistance and lowers inflammatory cytokines in aging humans. Aging (Albany NY) 3:533–542
Andus T, Klebl F, Rogler G, Bregenzer N, Scholmerich J, Straub RH (2003) Patients with refractory Crohn’s disease or ulcerative colitis respond to dehydroepiandrosterone: a pilot study. Aliment Pharmacol Ther 17:409–414
Chang DM, Lan JL, Lin HY, Luo SF (2002) Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46:2924–2927
Altman R, Motton DD, Kota RS, Rutledge JC (2008) Inhibition of vascular inflammation by dehydroepiandrosterone sulfate in human aortic endothelial cells: roles of PPARalpha and NF-kappaB. Vasc Pharmacol 48:76–84
Fusi FM, Ferrario M, Bosisio C, Arnoldi M, Zanga L (2013) DHEA supplementation positively affects spontaneous pregnancies in women with diminished ovarian function. Gynecol Endocrinol 29:940–943
Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dube R, Cote I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J (2009a) Effect of intravaginal dehydroepiandrosterone (prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause 16:923–931
Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dube R, Cote I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J (2009b) Intravaginal dehydroepiandrosterone (prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause 16:907–922
do Vale S, Selinger L, Martins JM, Bicho M, do Carmo I, Escera C (2015) Dehydroepiandrosterone (DHEA) and dehydroepiandrosterone-sulfate (DHEAS) and emotional processing - a behavioral and electrophysiological approach. Horm Behav 73:94–103
Wolkowitz OM, Reus VI, Roberts E, Manfredi F, Chan T, Raum WJ, Ormiston S, Johnson R, Canick J, Brizendine L, Weingartner H (1997) Dehydroepiandrosterone (DHEA) treatment of depression. Biol Psychiatry 41:311–318
Joshi K, Hassan SS, Ramaraj P (2017) Differential biological effects of dehydroepiandrosterone (DHEA) between mouse (B16F10) and human melanoma (BLM) cell lines. Dermatoendocrinol 9:e1389360
Lin H, Li L, Wang Q, Wang Y, Wang J, Long X (2019a) A systematic review and meta-analysis of randomized placebo-controlled trials of DHEA supplementation of bone mineral density in healthy adults. Gynecol Endocrinol 35:924–931
Papierska L, Rabijewski M, Kasperlik-Zaluska A, Zgliczynski W (2012) Effect of DHEA supplementation on serum IGF-1, osteocalcin, and bone mineral density in postmenopausal, glucocorticoid-treated women. Adv Med Sci 57:51–57
Weiss EP, Shah K, Fontana L, Lambert CP, Holloszy JO, Villareal DT (2009) Dehydroepiandrosterone replacement therapy in older adults: 1- and 2-y effects on bone. Am J Clin Nutr 89:1459–1467
Nair KS, Rizza RA, O’Brien P, Dhatariya K, Short KR, Nehra A, Vittone JL, Klee GG, Basu A, Basu R, Cobelli C, Toffolo G, Dalla Man C, Tindall DJ, Melton LJ 3rd, Smith GE, Khosla S, Jensen MD (2006) DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 355:1647–1659
Sun Y, Mao M, Sun L, Feng Y, Yang J, Shen P (2002) Treatment of osteoporosis in men using dehydroepiandrosterone sulfate. Chin Med J 115:402–404
Baulieu EE, Thomas G, Legrain S, Lahlou N, Roger M, Debuire B, Faucounau V, Girard L, Hervy MP, Latour F, Leaud MC, Mokrane A, Pitti-Ferrandi H, Trivalle C, de Lacharriere O, Nouveau S, Rakoto-Arison B, Souberbielle JC, Raison J, Le Bouc Y, Raynaud A, Girerd X, Forette F (2000) Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci U S A 97:4279–4284
Adams J, Garcia M, Rochefort H (1981) Estrogenic effects of physiological concentrations of 5-androstene-3 beta, 17 beta-diol and its metabolism in MCF7 human breast cancer cells. Cancer Res 41:4720–4726
Labrie F, Belanger A, Cusan L, Candas B (1997) Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology. J Clin Endocrinol Metab 82:2403–2409
Panjari M, Bell RJ, Jane F, Adams J, Morrow C, Davis SR (2009) The safety of 52 weeks of oral DHEA therapy for postmenopausal women. Maturitas 63:240–245
Scheffers CS, Armstrong S, Cantineau AE, Farquhar C, Jordan V (2015) Dehydroepiandrosterone for women in the peri- or postmenopausal phase. Cochrane Database Syst Rev 1:CD011066
Kushnir MM, Blamires T, Rockwood AL, Roberts WL, Yue B, Erdogan E, Bunker AM, Meikle AW (2010) Liquid chromatography-tandem mass spectrometry assay for androstenedione, dehydroepiandrosterone, and testosterone with pediatric and adult reference intervals. Clin Chem 56:1138–1147
Dhatariya KK, Nair KS (2003) Dehydroepiandrosterone: is there a role for replacement? Mayo Clin Proc 78:1257–1273
Leowattana W (2004) DHEAS as a new diagnostic tool. Clin Chim Acta 341:1–15
Dumas de la Roque E, Quignard JF, Ducret T, Dahan D, Courtois A, Begueret H, Marthan R, Savineau JP (2013) Beneficial effect of dehydroepiandrosterone on pulmonary hypertension in a rodent model of pulmonary hypertension in infants. Pediatr Res 74:163–169
Maninger N, Wolkowitz OM, Reus VI, Epel ES, Mellon SH (2009) Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS). Front Neuroendocrinol 30:65–91
Savineau JP, Marthan R, Dumas de la Roque E (2013) Role of DHEA in cardiovascular diseases. Biochem Pharmacol 85:718–726
Webb SJ, Geoghegan TE, Prough RA, Michael Miller KK (2006) The biological actions of dehydroepiandrosterone involves multiple receptors. Drug Metab Rev 38:89–116
Binello E, Gordon CM (2003) Clinical uses and misuses of dehydroepiandrosterone. Curr Opin Pharmacol 3:635–641
Yue J, Wang L, Huang R, Li S, Ma J, Teng X, Liu W (2013) Dehydroepiandrosterone-sulfate (DHEAS) promotes MIN6 cells insulin secretion via inhibition of AMP-activated protein kinase. Biochem Biophys Res Commun 440:756–761
Aoki K, Terauchi Y (2018) Effect of dehydroepiandrosterone (DHEA) on diabetes mellitus and obesity. Vitam Horm 108:355–365
Kasperk CH, Wakley GK, Hierl T, Ziegler R (1997) Gonadal and adrenal androgens are potent regulators of human bone cell metabolism in vitro. J Bone Miner Res 12:464–471
Lemmen JG, van den Brink CE, Legler J, van der Saag PT, van der Burg B (2002) Detection of oestrogenic activity of steroids present during mammalian gestation using oestrogen receptor alpha- and oestrogen receptor beta-specific in vitro assays. J Endocrinol 174:435–446
Wang L, Wang YD, Wang WJ, Zhu Y, Li DJ (2007) Dehydroepiandrosterone improves murine osteoblast growth and bone tissue morphometry via mitogen-activated protein kinase signaling pathway independent of either androgen receptor or estrogen receptor. J Mol Endocrinol 38:467–479
Liu D, Dillon JS (2002) Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Galpha(i2,3). J Biol Chem 277:21379–21388
Liang X, Glowacki J, Hahne J, Xie L, LeBoff MS, Zhou S (2016) Dehydroepiandrosterone stimulation of osteoblastogenesis in human MSCs requires IGF-I signaling. J Cell Biochem 117:1769–1774
Blume SW, Curtis JR (2011) Medical costs of osteoporosis in the elderly Medicare population. Osteoporos Int 22:1835–1844
Wright NC, Looker AC, Saag KG, Curtis JR, Delzell ES, Randall S, Dawson-Hughes B (2014) The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res 29:2520–2526
Clarke BL, Ebeling PR, Jones JD, Wahner HW, O’Fallon WM, Riggs BL, Fitzpatrick LA (2002) Predictors of bone mineral density in aging healthy men varies by skeletal site. Calcif Tissue Int 70:137–145
Gordon CM, Glowacki J, LeBoff MS (1999) DHEA and the skeleton (through the ages). Endocrine 11:1–11
Davison SL, Bell R, Donath S, Montalto JG, Davis SR (2005) Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab 90:3847–3853
Orentreich, N., J. L. Brind, R. L. Rizer, and J. H. Vogelman. 1984. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood, J Clin Endocrinol Metab, 59: 551-5, 555.
Ohlsson C, Nethander M, Kindmark A, Ljunggren O, Lorentzon M, Rosengren BE, Karlsson MK, Mellstrom D, Vandenput L (2017) Low serum DHEAS predicts increased fracture risk in older men: the MrOS Sweden Study. J Bone Miner Res 32:1607–1614
Ohlsson C, Nethander M, Karlsson MK, Rosengren BE, Ribom E, Mellstrom D, Vandenput L (2018) Serum DHEA and its sulfate are associated with incident fall risk in older men: the MrOS Sweden Study. J Bone Miner Res 33:1227–1232
Luo S, Labrie C, Belanger A, Labrie F (1997) Effect of dehydroepiandrosterone on bone mass, serum lipids, and dimethylbenz(a)anthracene-induced mammary carcinoma in the rat. Endocrinology 138:3387–3394
Martel C, Sourla A, Pelletier G, Labrie C, Fournier M, Picard S, Li S, Stojanovic M, Labrie F (1998) Predominant androgenic component in the stimulatory effect of dehydroepiandrosterone on bone mineral density in the rat. J Endocrinol 157:433–442
Turner RT, Lifrak ET, Beckner M, Wakley GK, Hannon KS, Parker LN (1990) Dehydroepiandrosterone reduces cancellous bone osteopenia in ovariectomized rats. Am J Phys 258:E673–E677
Zhang N, Gui Y, Qiu X, Tang W, Li L, Gober HJ, Li D, Wang L (2016) DHEA prevents bone loss by suppressing the expansion of CD4(+) T cells and TNFa production in the OVX-mouse model for postmenopausal osteoporosis. Biosci Trends 10:277–287
Jankowski CM, Wolfe P, Schmiege SJ, Nair KS, Khosla S, Jensen M, von Muhlen D, Laughlin GA, Kritz-Silverstein D, Bergstrom J, Bettencourt R, Weiss EP, Villareal DT, Kohrt WM (2019) Sex-specific effects of dehydroepiandrosterone (DHEA) on bone mineral density and body composition: a pooled analysis of four clinical trials. Clin Endocrinol 90:293–300
Zuo C, Huang Y, Bajis R, Sahih M, Li YP, Dai K, Zhang X (2012) Osteoblastogenesis regulation signals in bone remodeling. Osteoporos Int 23:1653–1663
Qiu X, Gui Y, Xu Y, Li D, Wang L (2015) DHEA promotes osteoblast differentiation by regulating the expression of osteoblast-related genes and Foxp3(+) regulatory T cells. Biosci Trends 9:307–314
Langley, E., R. Velazquez-Cruz, A. Parra-Torres, and J. Enriquez. 2018. The non-aromatic Delta5-androstenediol derivative of dehydroepiandrosterone acts as an estrogen agonist in neonatal rat osteoblasts through an estrogen receptor alpha-related mechanism, Endocr Res: 1-16.
Lin, H., L. Li, Q. Wang, Y. Wang, J. Wang, and X. Long. 2019b. A systematic review and meta-analysis of randomized placebo-controlled trials of DHEA supplementation of bone mineral density in healthy adults, Gynecol Endocrinol: 1-8
Wang YD, Tao MF, Cheng WW, Liu XH, Wan XP, Cui K (2012) Dehydroepiandrosterone indirectly inhibits human osteoclastic resorption via activating osteoblastic viability by the MAPK pathway. Chin Med J 125:1230–1235
Harding G, Mak YT, Evans B, Cheung J, MacDonald D, Hampson G (2006) The effects of dexamethasone and dehydroepiandrosterone (DHEA) on cytokines and receptor expression in a human osteoblastic cell line: potential steroid-sparing role for DHEA. Cytokine 36:57–68
Takayanagi R, Goto K, Suzuki S, Tanaka S, Shimoda S, Nawata H (2002) Dehydroepiandrosterone (DHEA) as a possible source for estrogen formation in bone cells: correlation between bone mineral density and serum DHEA-sulfate concentration in postmenopausal women, and the presence of aromatase to be enhanced by 1,25-dihydroxyvitamin D3 in human osteoblasts. Mech Ageing Dev 123:1107–1114
Gordon CM, LeBoff MS, Glowacki J (2001) Adrenal and gonadal steroids inhibit IL-6 secretion by human marrow cells. Cytokine 16:178–186
Hofbauer LC, Ten RM, Khosla S (1999) The anti-androgen hydroxyflutamide and androgens inhibit interleukin-6 production by an androgen-responsive human osteoblastic cell line. J Bone Miner Res 14:1330–1337
Scheven BA, Milne JS (1998) Dehydroepiandrosterone (DHEA) and DHEA-S interact with 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) to stimulate human osteoblastic cell differentiation. Life Sci 62:59–68
Hierl T, Borcsok I, Sommer U, Ziegler R, Kasperk C (1998) Regulation of interleukin-6 expression in human osteoblastic cells in vitro. Exp Clin Endocrinol Diabetes 106:324–333
Tanaka S, Haji M, Takayanagi R, Tanaka S, Sugioka Y, Nawata H (1996) 1,25-Dihydroxyvitamin D3 enhances the enzymatic activity and expression of the messenger ribonucleic acid for aromatase cytochrome P450 synergistically with dexamethasone depending on the vitamin D receptor level in cultured human osteoblasts. Endocrinology 137:1860–1869
Bodine PV, Riggs BL, Spelsberg TC (1995) Regulation of c-fos expression and TGF-beta production by gonadal and adrenal androgens in normal human osteoblastic cells. J Steroid Biochem Mol Biol 52:149–158
Sun H, Zang W, Zhou B, Xu L, Wu S (2011) DHEA suppresses longitudinal bone growth by acting directly at growth plate through estrogen receptors. Endocrinology 152:1423–1433
Wang YD, Wang L, Li DJ, Wang WJ (2006) Dehydroepiandrosterone inhibited the bone resorption through the upregulation of OPG/RANKL. Cell Mol Immunol 3:41–45
Takeuchi S, Mukai N, Tateishi T, Miyakawa S (2007) Production of sex steroid hormones from DHEA in articular chondrocyte of rats. Am J Physiol Endocrinol Metab 293:E410–E415
Sun JS, Wu CX, Tsuang YH, Chen LT, Sheu SY (2006) The in vitro effects of dehydroepiandrosterone on chondrocyte metabolism. Osteoarthr Cartil 14:238–249
Jo H, Park JS, Kim EM, Jung MY, Lee SH, Seong SC, Park SC, Kim HJ, Lee MC (2003) The in vitro effects of dehydroepiandrosterone on human osteoarthritic chondrocytes. Osteoarthr Cartil 11:585–594
Li W, Tang L, Xiong Y, Zhou X, Wu L (2013) The chondroprotective effects of dehydroepiandrosterone probably exerted by its conversion to estradiol. J Steroid Biochem Mol Biol 134:15–22
Boker J, Volzke H, Nauck M, Hannemann A, Friedrich N (2018) Associations of insulin-like growth factor-I and insulin-like growth factor binding protein-3 with bone quality in the general adult population. Clin Endocrinol 88:830–837
Janssen JA, Burger H, Stolk RP, Grobbee DE, de Jong FH, Lamberts SW, Pols HA (1998) Gender-specific relationship between serum free and total IGF-I and bone mineral density in elderly men and women. Eur J Endocrinol 138:627–632
Seck T, Scheidt-Nave C, Leidig-Bruckner G, Ziegler R, Pfeilschifter J (2001) Low serum concentrations of insulin-like growth factor I are associated with femoral bone loss in a population-based sample of postmenopausal women. Clin Endocrinol 55:101–106
Hock JM, Centrella M, Canalis E (1988) Insulin-like growth factor I has independent effects on bone matrix formation and cell replication. Endocrinology 122:254–260
Locatelli V, Bianchi VE (2014) Effect of GH/IGF-1 on bone metabolism and osteoporsosis. Int J Endocrinol 2014:235060
Weiss S, Henle P, Bidlingmaier M, Moghaddam A, Kasten P, Zimmermann G (2008) Systemic response of the GH/IGF-I axis in timely versus delayed fracture healing. Growth Hormon IGF Res 18:205–212
Morales AJ, Haubrich RH, Hwang JY, Asakura H, Yen SS (1998) The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol 49:421–432
Xie, M., Y. Zhong, Q. Xue, M. Wu, X. Deng, O. Santos H, S. C. Tan, H. Kord-Varkaneh, and P. Jiao. 2020. Impact of dehydroepianrosterone (DHEA) supplementation on serum levels of insulin-like growth factor 1 (IGF-1): a dose-response meta-analysis of randomized controlled trials, Exp Gerontol, 136: 110949.
Schmidmaier G, Wildemann B, Heeger J, Gabelein T, Flyvbjerg A, Bail HJ, Raschke M (2002) Improvement of fracture healing by systemic administration of growth hormone and local application of insulin-like growth factor-1 and transforming growth factor-beta1. Bone 31:165–172
Andreassen TT, Oxlund H (2003) Local anabolic effects of growth hormone on intact bone and healing fractures in rats. Calcif Tissue Int 73:258–264
Bail HJ, Kolbeck S, Krummrey G, Schmidmaier G, Haas NP, Raschke MJ (2002) Systemic application of growth hormone for enhancement of secondary and intramembranous fracture healing. Horm Res 58(Suppl 3):39–42
Nielsen HM, Bak B, Jorgensen PH, Andreassen TT (1991) Growth hormone promotes healing of tibial fractures in the rat. Acta Orthop Scand 62:244–247
Boonen S, Rosen C, Bouillon R, Sommer A, McKay M, Rosen D, Adams S, Broos P, Lenaerts J, Raus J, Vanderschueren D, Geusens P (2002) Musculoskeletal effects of the recombinant human IGF-I/IGF binding protein-3 complex in osteoporotic patients with proximal femoral fracture: a double-blind, placebo-controlled pilot study. J Clin Endocrinol Metab 87:1593–1599
Van der Lely AJ, Lamberts SW, Jauch KW, Swierstra BA, Hertlein H, Danielle De Vries D, Birkett MA, Bates PC, Blum WF, Attanasio AF (2000) Use of human GH in elderly patients with accidental hip fracture. Eur J Endocrinol 143:585–592
Hintz RL (2004) Growth hormone: uses and abuses. BMJ 328:907–908
Code availability
Not applicable
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
This article does not contain any studies with human participants or animals performed by any of the authors.
Conflicts of interest
None.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Kirby, D.J., Buchalter, D.B., Anil, U. et al. DHEA in bone: the role in osteoporosis and fracture healing. Arch Osteoporos 15, 84 (2020). https://doi.org/10.1007/s11657-020-00755-y
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s11657-020-00755-y